Eliot Choy is counsel in the Corporate Department of the New York office of Latham & Watkins, where his practice focuses on technology-related transactions within the healthcare and life sciences industries.

Mr. Choy advises and counsels pharmaceutical and biotech companies on a range of complex commercial matters, including intellectual property licenses, commercial development and other strategic collaborations, and product divestitures and acquisitions.

His extensive experience includes structuring and negotiating various types of agreements involving the transfer, use, and sharing of intellectual property, including agreements covering the research, development, licensing, supply, manufacturing, promotion, and marketing and distribution of pharmaceutical drug products. He also advises branded and generic pharmaceutical companies in the settlement of patent litigations and related commercial matters.

In addition, Mr. Choy has experience in advising private and publicly held companies in a variety of corporate transactions, including stock- and asset-based transactions, venture capital and strategic investments, and public and private securities offerings.

Representative clients include:

  • Acino
  • Aerie Pharmaceuticals
  • Allergan
  • Atnahs Pharma
  • Baxter Healthcare
  • Eagle Pharmaceuticals
  • Endo Ventures Limited
  • GlaxoSmithKline
  • Mallinckrodt
  • Sobi
  • Theramex

Representative transactions include:

  • Aerie Pharmaceuticals in connection with an exclusive development and commercialization agreement with Santen Pharmaceuticals for Rhopressa and Rocklatan in Japan, along with rights for several other Asian countries
  • Swedish Orphan Biovitrum AB (publ) (Sobi™) on a variety of matters, including:
    • Its strategic licensing and collaboration agreement with Apellis Pharmaceuticals Inc. for co-development and exclusive ex-US commercialization rights for systemic pegcetacoplan
    • Its strategic licensing agreement with Selecta Biosciences for a phase-3 ready therapy for the treatment of chronic refractory gout
    • Its acquisition of rights to Synagis in the US from AstraZeneca
  • Oasmia Pharmaceutical on its global strategic partnership for the development and commercialization of its proprietary anticancer product with Elevar Therapeutics
  • Atnahs Pharma on its acquisition of assets related to five hypertension medicine brands from AstraZeneca
  • Acino on its acquisition of certain pain management, gastroenterology, cardiovascular, and respiratory products from Takeda Pharmaceuticals
  • Amgen in connection with its strategic collaboration with BeiGene to commercialize medicines from Amgen’s oncology pipeline in China
  • GSK on a variety of matters, including the divestment of its Prevacid®24HR business to Perrigo Company
  • ICU Medical on its US$1 billion cash and stock acquisition of Pfizer's global infusion therapy business
  • Allergan in connection with its divestment of its global generic pharmaceuticals business and the rights to certain branded products to Teva for US$40.6 billion
  • Branded and generic pharmaceutical companies in connection with a variety of matters, including:
    • Strategic alliances and collaborations with and between other pharmaceutical drug companies
    • The acquisition and divestiture of abbreviated new drug applications and new drug applications for pharmaceutical products (including in connection with regulatory divestiture requirements)
    • The launch and marketing of authorized generic pharmaceutical products
    • Licensing and other commercial arrangements in connection the settlement of patent infringement claims

Bar Qualification

  • New York


  • BA, University of California, Los Angeles
  • JD, Boston University School of Law